FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...
Dan Rizzo, global head of Veeva Business Consulting, spoke with Pharmaceutical Executive about the state of product launches ...
Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...
Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares ...
In a statement sent to Pharmaceutical Executive, AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, said, “Although President Trump’s ...
A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback